![](https://cdn.sanity.io/images/0vv8moc6/ajmc/ff9ffbca858fbb2833bf65b18c99e5a9c74b8707-1200x738.jpg?fit=crop&auto=format)
FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL
The triplet therapy of brentuximab vedotin (Adcetris; Seagen), lenalidomide, and a rituximab product was approved late yesterday by the FDA to treat relapsed or refractory large B-cell lymphoma (LBCL), including diffuse LBCL (DLBCL) not otherwise specified …